|Dr. Michael Winlo||MD & Director||421.04k||N/A||N/A|
|Dr. Alistair Vickery||Executive Medical Director & Director||381.42k||N/A||N/A|
|Mr. Joseph Daniel Ohayon ACA, MBA Intl Bus.||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Sara Polanski||Communications & Brand Manager||N/A||N/A||N/A|
|Ms. Tracie Ernenwein||Head of Research & Drug Development||N/A||N/A||N/A|
|Mary-Ann Rennie||Head of Corporate Operations||N/A||N/A||N/A|
|Ms. Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., F Fin, FCIS||Company Secretary||N/A||N/A||1975|
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
Emyria Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.